Pfizer reaffirmed its 2026 outlook, expecting full-year adjusted profit to come in between $2.80 and $3 per share, and ...
Pfizer said on ​Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its ‌heart drug Vyndamax and a favorable European court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results